Biomotion Sciences Ordinary Shares

$0.85
(as of Jun 16, 11:08 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Biomotion Sciences Ordinary Shares

Stock Price
$0.85
Ticker Symbol
SLXN
Exchange
NASDAQ

Industry Information for Biomotion Sciences Ordinary Shares

Sector
Healthcare
Industry
Biotechnology

Company Description for Biomotion Sciences Ordinary Shares

Website
https://silexion.com
Country
USA
Full Time Employees
11

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Fundamentals for Biomotion Sciences Ordinary Shares

Market Capitalization
$9,866,084
EBITDA
$-1,355,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.66
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
9,768,400
Percent Owned by Insiders
93.76%
Percent Owned by Institutions
13.13%
52-Week High
52-Week Low

Technical Indicators for Biomotion Sciences Ordinary Shares

50-Day Moving Average
200-Day Moving Average
RSI
40.85
ATR
0.08

Analyst Ratings for Biomotion Sciences Ordinary Shares

Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0

News About Biomotion Sciences Ordinary Shares

May 29, 2025, 11:43 PM EST
Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three major KRAS-driven cancers: pancreatic, colorectal, and lung (NSCLC). See more.
May 29, 2025, 9:05 AM EST
GRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. See more.
May 21, 2025, 8:45 AM EST
GRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the completion of a comprehensive preclinical study assessing SIL204's therapeutic potential across multiple cancer types beyond pancreatic cancer. See more.
May 13, 2025, 4:45 PM EST
GRAND CAYMAN, Cayman Islands, May 13, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. See more.